Frontiers in Anti-Infective Drug Discovery is a valuable resource for pharmaceutical scientists and post-graduate students seeking updated and critically important information for developing clinical trials and devising research plans in this field. The tenth volume of this series features 4 reviews on the following topics: -Pharmacotherapy of Posterior Segment Ocular Infections -Discovery and Development of Antimalarial Drug-Resistance Reversal Agents -Omics Technologies and Anti-Infective Drug Discovery -Possible Cutaneous Adverse Effects of Anti-Infective Vaccinations

COVID-19 has spread like wildfire across the globe since the start of the SARS-CoV-2 outbreak, hampering quality of life at multiple levels and causing many deaths. Many aspects of the human experience have been affected, with a body of research being published on its effects on psychological and physical well being, loss of jobs, pay cuts, education, and unpaid caregiving. New findings on these aspects are still emerging as we learn more about the consequences of the pandemic. This book is intended as a simple summary of recent findings about COVID-19 for academicians and students from science, humanities and commerce backgrounds to understand the pandemic from a microscopic view and how it has touched our lives at different levels. A collection of topics is presented and explored through chapters dedicated to niche topics on COVID-19. Each chapter is authored by expert scientists, academicians and scholars from leading institutions in India. The key features of this book set are: - Interdisciplinary content, making it useful for readers from different academic streams - A blend of basic and applied research in biology, medicine and social science - A focus on findings from India - Updated References for advanced readers This collection of topics is invaluable for researchers and working professionals in industry and academia as well as general readers who want a broad, insightful perspective on COVID-19.

The immune system is highly complex, it senses foreign invaders, thus protecting the body. The adaptive arm of the immune system confers long-term protection, whereas the innate immune system confers immediate protection. The immune system uses pattern recognition receptors that are able to sense the molecular patterns associated with pathogens. Toll-like receptors (TLRs) are important mediators of inflammatory pathways in the gut which play a major role in mediating the immune responses towards a wide variety of pathogen-derived ligands and link adaptive immunity with the innate immunity. This book covers the role of TLRs in several vector-borne Diseases. Starting with an introduction to these diseases, the book explains the different types of receptors involved in these diseases. The diseases are then covered in separate chapters, including: malaria, lymphatic filariasis, visceral leishmaniasis, dengue fever, chikungunya, West Nile fever, and Japanese encephalitis. The book is a handy reference for researchers and trainees involved in clinical medicine and infection control. It can also serve as supplementary reading material for Students undertaking courses in biotechnology, public health, entomology, immunology, epidemiology, and life sciences.

Drug repurposing is a cost-effective method of discovering new treatments for diseases than traditional drug development methods. It involves virtual screening of chemical candidates with the aid of computational methods like molecular docking. Drug Repurposing against SARS-CoV2 focuses on current trends in drug repurposing against the novel coronavirus strains. The book aims to give readers an overview of drug repurposing against COVID-19 and various techniques involved in the process. The book consolidates available information on the pathophysiology, drug targets, and drug repurposing against COVID-19 into a single, convenient resource. Key features -An up-to-date compilation of the evidence that supports the drug repurposing for COVID-19. -How to use repurposing of available drugs for disease therapy. -Provides an improved understanding of pathophysiology and SARS-CoV2 viral entry pathways. - Provides references for further reading

Despite an increase in life expectancy over the past 20 years, the number of novel, multi-drug resistant microorganisms has also risen dramatically. To reduce the risk of reemerging infections, and limit the spread of multidrug resistant microorganisms, it is urgently necessary to develop safe and effective therapeutic countermeasures. New antimicrobial chemicals are mostly produced with the help of microorganisms, and the bulk of medications now on the market are of this type. The use of high therapeutic screening and recent developments in analytical instrumentation has allowed the researchers to identify novel antimicrobial compounds from bacteria, fungi, plants, mushrooms, algae, and other sources more quickly. The second volume of Frontiers in Antimicrobial Agents highlights the ongoing requirement for researching and creating novel antimicrobial medications. Current Trends in the Identification and Development of Antimicrobial Agents aims to bring together the expertise of notable academics to examine all facets of antimicrobial research while keeping recent advancements in perspective. Antibiotic discovery, sources of novel antimicrobial chemicals, developing and reemerging microbial infections, various elements of drug resistance, and the need for antimicrobial medications in the future are all covered in this book. It is a timely reference for anyone involved in the discovery and development of new drugs, including microbiologists, biotechnologists, pharmacologists, doctors, and researchers.

Recent Trends and the Future of Antimicrobial Agents provides a significantly expanded overview of the topic with updated research in a broader context on the development of alternative approaches against microbial infections. This part consists of ten chapters. The first five chapters describe naturally derived antimicrobial compounds such as plant-based antimicrobials (PBAs), enzymes-based and antibody-based antibacterial therapeutic and secondary metabolites from plant endophytes. The book proceeds to provide details about antimicrobials derived from marine microorganisms (bacteria, fungi, actinomycetes, and cyanobacteria) is included to inform readers about effective medications against MDR strains. Specific chapters describe the drug development against protozoans, with one chapter focusing on Plasmodium. Chapter contributors have postulated novel approaches for antimalarial therapeutics. The book also includes an explanation of host target identification and drug discovery with the purpose of informing the reader about the implications in viral biology and how they could be exploited for treating viral diseases. The contents cater to the information needs of professionals and learners in academia, industry and health services who aim to learn the most significant experimental and practical approaches towards finding alternatives to existing antimicrobial therapies.

The burden of hepatitis C virus (HCV) infection on the public health care system continues to remain significant despite the remarkable progress made in HCV therapeutics in the recent past. There are now almost a dozen oral interferon-free direct-acting antivirals available for the treatment of hepatitis C virus infection. Despite advances in the treatment of HCV, therapeutic gaps remain that are yet to be fully explored. Researchers and scientists still strive to understand virus-host interactions to map the disease's progression along with extrahepatic manifestations and virus invasion strategies impacting the host's immune system. This book briefly discusses the biology of HCV infection, virus-host interactions, molecular epidemiology of the infection, and the full spectrum of immune responses to hepatitis C. It also provides in-depth information about HCV, clinical diagnostics, and therapeutic knowledge to all stakeholders involved in HCV screening, diagnosis, treatment, and management. Topics covered in the chapters include 1) HCV-host interactions leading to asymptomatic acute infection, 2) the progression of acute HCV infection to chronic disease and subsequent extrahepatic comorbidities, 3) Innate and adaptive immune responses in HCV infections, 4) Consensus-based Approaches for Hepatitis C Screening and Diagnosis, 5) advances in hepatitis C therapy and global management of HCV, and 6) the outcomes of Oral Interferon-free Direct-acting Antivirals as Combination Therapies to Cure Hepatitis C. This book is a valuable addition to undergraduate and postgraduate hepatology students and physicians, clinicians, hepatologists, and health care officials involved in HCV clinical diagnosis and therapeutics.

In this third year of the SARS-CoV-2 pandemic responsible for COVD-19 and related diseases worldwide, the scientific studies and reviews focused on this virus and its variants are still crucial. The third volume of the Coronaviruses series brings together some essential data regarding the origin, pathology and chemotherapeutic drugs to treat coronavirus infections. Contributions are written by experienced researchers with the goal of updating medical researchers and clinicians dealing with COVID-19 patients. It presents seven chapters covering a range of topics: (1) bat coronaviruses in the world, (2) hospital challenges during the COVID-19 pandemic, (3) the pro-inflammatory and thrombotic manifestations and the therapeutic options of Covid-19, (4) the common and rare dermatologic manifestations registered in COVID-19 patients, (5) the circulating biomarkers of cardiopulmonary disturbances in COVID-19, and (6) the aspects of pathology and pathogenesis of coronavirus infection

This compendium represents a set of guides to understanding the challenging scientific, epidemiological, clinical, social, and economic phenomenon that is represented by the COVID-19 pandemic. The book explains the mathematical modeling of COVID-19 infection, with emphasis on traditional epidemiological principles. It represents a rigorous, comprehensive and multidisciplinary approach to a complex phenomenon. The chapters take into account the knowledge arising from different disciplines (epidemiology, pathophysiology, immunology, medicine, biology, vaccine development, etc.). It also covers COVID-19 data analysis, giving the reader a perspective of statistics and data science, and includes a discussion about social and economic issues of the pandemic. Each chapter is devoted to a specific topic, and is contributed by experts in epidemiology. Because of its multidisciplinary nature, this book is intended as a reference on mathematical models and basic immunotherapy for COVID-19 for a broad community of readers, from scholars who have scientific training, to general readers who have an interest in the disease.

This book provides an update on heterocyclic compounds that serve as key components of anti-cancer agents administered in pre-clinical settings. Many of the compounds highlighted in the book are being actively investigated for the bioactive properties against a range of cancer cell lines. There is potential for heterocyclic compounds to design agents that can target specific molecules to treat different types of cancers. Chapters are contributed by experts in pharmaceutical chemistry and are written to give a general overview of the topic to readers involved in all levels of research and decision-making in pharmaceutical chemistry and anti-cancer drug design. Part II of the book set covers these topics: - Anticancer targets for heterocyclic lead compounds - Coumarin hybrids for cancer treatments - Progress in nitrogen and sulphur-based heterocyclic compounds for their anticancer activity - Imidazole as an anticancer heterocyclic ring - Morpholine for profiling anticancer lead compounds - Natural products as anticancer agents